These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20216222)

  • 21. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
    Datto C; Berggren L; Patel JB; Eriksson H
    Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kahn RS; Schulz SC; Palazov VD; Reyes EB; Brecher M; Svensson O; Andersson HM; Meulien D;
    J Clin Psychiatry; 2007 Jun; 68(6):832-42. PubMed ID: 17592906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study.
    Cookson J; Keck PE; Ketter TA; Macfadden W
    Int Clin Psychopharmacol; 2007 Mar; 22(2):93-100. PubMed ID: 17293709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.
    Bortnick B; El-Khalili N; Banov M; Adson D; Datto C; Raines S; Earley W; Eriksson H
    J Affect Disord; 2011 Jan; 128(1-2):83-94. PubMed ID: 20691481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
    Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
    J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
    De Deyn PP; Eriksson H; Svensson H;
    Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.
    Peuskens J; Trivedi J; Malyarov S; Brecher M; Svensson O; Miller F; Persson I; Meulien D
    Psychiatry (Edgmont); 2007 Nov; 4(11):34-50. PubMed ID: 20428302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quetiapine in schizophrenia: onset of action within the first week of treatment.
    Small JG; Kolar MC; Kellams JJ
    Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
    Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
    J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.
    Clayton AH; Locklear JC; Svedsäter H; McIntyre RS
    CNS Spectr; 2014 Apr; 19(2):182-96. PubMed ID: 24067192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
    Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
    Kasper S; Montagnani G; Trespi G; Di Fiorino M
    Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine XR: current status for the treatment of major depressive disorder.
    Pae CU; Sohi MS; Seo HJ; Serretti A; Patkar AA; Steffens DC; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1165-73. PubMed ID: 20307622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
    Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia.
    Lee JG; Lee JI; Kim YT; Kim CE; Kim CY; Yoon JS; Yoo SY; Kim YH
    Hum Psychopharmacol; 2012 Jul; 27(4):403-10. PubMed ID: 22753400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies.
    Weisler R; Montgomery SA; Earley WR; Szamosi J; Eriksson H
    J Clin Psychiatry; 2014 May; 75(5):520-7. PubMed ID: 24816198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
    Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
    J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.